Cell Signaling Technology to Conduct Pilot Study for AstraZeneca to Find Biomarkers of Target Inhibition

Jun 08, 2004

NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Main menu